System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD79b

CB3-1 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-676-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-676-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1F-676-T025 FITC 25 tests yes choose region PDF datasheetHTML datasheet buy
  1F-676-T100 FITC 100 tests yes choose region PDF datasheetHTML datasheet buy
  1P-676-T025 PE 25 tests yes choose region PDF datasheetHTML datasheet buy
  1P-676-T100 PE 100 tests yes choose region PDF datasheetHTML datasheet buy
  1A-676-T025 APC 25 tests yes choose region PDF datasheetHTML datasheet buy
  1A-676-T100 APC 100 tests yes choose region PDF datasheetHTML datasheet buy
  T9-676-T025 PerCP-Cy™5.5 25 tests yes choose region PDF datasheetHTML datasheet buy
  T9-676-T100 PerCP-Cy™5.5 100 tests yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Specificity

The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex.
HLDA VI.; WS Code CD79.1

Regulatory Status

Immunogen

Fraction of Ig-associated molecules isolated from Ramos B cells

Species Reactivity:

  • Human

Negative Species:

Applications:

  • Flow Cytometry
  • Immunoprecipitation
  • Western Blotting
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8522-6. [Abstract] [Full Text]
  • *Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8(10):2937-46. [Abstract] [Full Text]
  • *Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13(10):1501-5. [Abstract]
  • *Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7. [Abstract] [Full Text]
  • *Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9. [Abstract] [Full Text]
  • *Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55(3):180-3. [Abstract] [Full Text]
  • *D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85(5):556-7. [Abstract] [Full Text]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    CB3-1 PerCP-Cy5-5


    Fig. 1. Surface staining of CD79b in human peripheral blood with anti-CD79b (CB3-1) PerCP-Cy5.5.


    CB3-1 FITC


    Fig. 2. Surface staining of CD79b in human peripheral blood with anti-CD79b (CB3-1) FITC.


    CB3-1 PE FC


    Fig. 3. Surface staining of CD79b in human peripheral blood with anti-CD79b (CB3-1) PE.



    CB3-1 APC


    Fig. 4. Surface staining of CD79b in human peripheral blood with anti-CD79b (CB3-1) APC.


    CB3-1 pur


    Fig. 5. Surface staining of CD79b in human peripheral blood with anti-CD79b (CB3-1) purified / GAM-APC.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at www.exbio.cz.
    Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registred trademarks of Molecular Probes Inc., Eugene, OR, USA. (licence label)
    DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
    Cy™ and CyDye™ are registered trademarks of GE Healthcare.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy